• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

1-Pyrrolidinecarboxylic acid, 3,3-difluoro-4-(hydroxymethyl)-, 1,1-dimethylethyl ester, (4S)-: A Comprehensive Overview

1-Pyrrolidinecarboxylic acid, 3,3-difluoro-4-(hydroxymethyl)-, 1,1-dimethylethyl ester, (4S)- is a sophisticated organic compound with a rich structural framework that has garnered significant attention in the field of pharmaceutical chemistry. This compound, identified by its CAS number 2199215-19-3, belongs to a class of molecules that exhibit promising biological activities. The intricate arrangement of its functional groups, including the pyrrolidine core, fluoro-substituents, and ester moiety, contributes to its unique chemical properties and potential therapeutic applications.

The< strong>pyrrolidine ring is a crucial structural element in many bioactive molecules due to its ability to mimic the conformation of natural amino acids. In this compound, the pyrrolidine ring is further modified with a fluoro-substituent at the 3-position and a hydroxymethyl group at the 4-position. These modifications enhance the compound's solubility and metabolic stability, making it an attractive candidate for drug development. Additionally, the presence of a< strong>1,1-dimethylethyl ester group at the 1-position adds another layer of structural complexity, which can influence its pharmacokinetic behavior.

The stereochemistry of this compound is also of great interest. The (4S) configuration indicates that the hydroxymethyl group is oriented in a specific spatial arrangement relative to the rest of the molecule. This chirality can have profound effects on the compound's biological activity and interactions with biological targets. Recent studies have shown that enantiomerically pure compounds often exhibit higher efficacy and fewer side effects compared to their racemic counterparts. Therefore, understanding and controlling the stereochemistry of this compound is essential for optimizing its therapeutic potential.

In recent years, there has been a growing interest in the development of fluorinated compounds for pharmaceutical applications. The introduction of fluorine atoms into organic molecules can significantly alter their physicochemical properties, such as lipophilicity, metabolic stability, and binding affinity. The< strong>fluoro-substituent in this compound is strategically placed at the 3-position of the pyrrolidine ring, which may enhance its interaction with biological targets by improving its binding affinity and resistance to enzymatic degradation.

The< strong>hydroxymethyl group at the 4-position of the pyrrolidine ring introduces a polar functional group that can participate in hydrogen bonding interactions. This feature can be exploited to improve the compound's solubility in water-based environments and enhance its bioavailability. Moreover, hydroxymethyl groups are often found in natural products and bioactive molecules, suggesting that this compound may have evolved or been designed to interact with specific biological pathways.

The< strong>1,1-dimethylethyl ester group at the 1-position of the pyrrolidine ring serves multiple purposes. It not only adds structural complexity but also influences the compound's metabolic fate. Ester groups are commonly found in pharmaceuticals due to their ability to be hydrolyzed into carboxylic acids under physiological conditions. This hydrolysis can be tailored to release active drug molecules at specific sites within the body or to control the duration of action of the drug.

The synthesis of< strong>1-Pyrrolidinecarboxylic acid, 3,3-difluoro-4-(hydroxymethyl)-, 1,1-dimethylethyl ester, (4S)- involves multiple steps that require precise control over reaction conditions and stereochemistry. Advanced synthetic techniques such as chiral resolution and asymmetric synthesis are often employed to obtain enantiomerically pure compounds. These methods ensure that only one enantiomer is produced during synthesis, which is critical for achieving desired biological activity while minimizing unwanted side effects.

In conclusion,< strong>1-Pyrrolidinecarboxylic acid, 3,3-difluoro-4-(hydroxymethyl)-, 1,1-dimethylethyl ester, (4S)- represents a fascinating example of how structural modifications can enhance biological activity and pharmacological properties. Its unique combination of functional groups and stereochemistry makes it a promising candidate for further research and development in pharmaceutical chemistry. As our understanding of molecular structure-activity relationships continues to evolve，this compound will likely play an important role in discovering new therapeutic agents for various diseases.

• 1260852-42-3(tert-Butyl 3,3-difluoro-4-(hydroxymethyl)pyrrolidine-1-carboxylate)
• 1627595-60-1(Tert-Butyl 4-(aminomethyl)-3,3-difluoropyrrolidine-1-carboxylate)
• 1428776-42-4(tert-butyl trans-3-fluoro-4-(hydroxymethyl)pyrrolidine-1-carboxylate)
• 1303974-47-1(tert-butyl 3,3-difluoro-4-(hydroxymethyl)piperidine-1-carboxylate)
• 1303973-24-1(Tert-butyl 4,4-difluoro-3-(hydroxymethyl)piperidine-1-carboxylate)
• 2165577-90-0(tert-butyl (R)-3,3-difluoro-4-(hydroxymethyl)piperidine-1-carboxylate)
• 1262412-64-5(tert-butyl 3,3-difluoro-5-(hydroxymethyl)piperidine-1-carboxylate)
• 2137997-74-9(Tert-butyl 5,5-difluoro-2,7-diazaspiro[3.4]octane-2-carboxylate)
• 1251000-89-1(tert-Butyl 8,8-difluoro-2,6-diazaspiro[3.4]octane-6-carboxylate)
• 1283720-61-5(Tert-butyl 3-(hydroxymethyl)-3-(trifluoromethyl)pyrrolidine-1-carboxylate)